Shelley Chu - Profile and Investment Details

Investor Profile

Shelley Chu is a Venture Capital, Private Equity Firm based in Menlo Park, California, United States with a diverse investment portfolio that includes companies such as Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin, CRISPR Therapeutics, Attenua, Broncus TechnologiesJasper Therapeutics, Synosia Therapeutics, X4 Pharmaceuticals, Kspine, Zogenix, PrimeraDx (Primera Biosystems), Scorpion Therapeutics, Avila Therapeutics, Personalis, MD On-Line, GenSight Biologics, Dicerna Pharmaceuticals, Verona Pharma, Micromet, Proteon Therapeutics, Prosensa, Stanmore Implants Worldwide, GTx, Median Technologies, Valeritas, Soleno Therapeutics, Wilson Therapeutics, Chroma Therapeutics, Avillion, Hydra Biosciences, Algeta, Sientra, Intellikine, Chiasma, Gynesonics, Reneo Pharmaceuticals, Vera Therapeutics, Portola Pharmaceuticals, Nouscom, Vaxcyte, Lombard Medical plc, Labcyte, Pathwork Diagnostics, Senseonics, Novexel, Clovis Oncology, Atsena Therapeutics, Cytos, VirionHealth, Phathom Pharmaceuticals, Fovea Pharmaceuticals, Venatorx Pharmaceuticals, IS Pharma, Effector Therapeutics, Sonitus Medical, Paratek Pharmaceuticals, Q32 Bio, GammaDelta Therapeutics, Tizona Therapeutics, Oxagen, SFJ Pharmaceuticals, Avedro, IFM Therapeutics, Virion Biotherapeutics, Realm Therapeutics, Pixium Vision, . Over time, Shelley Chu has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Shelley Chu is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Autoimmune Diseases, Wellness, Women Founded, Fundraising, Investment Management, Strategic Partnerships, Life Science, Portfolio Management, Finance, Biotechnology, Drug Development, Clinical Trials, Gene Therapy, Vaccines, Regulatory Compliance, Medical, B2B, Therapeutics, Pharmaceuticals may find it worthwhile to explore potential connections with Shelley Chu, as their portfolio suggests a familiarity and interest in this area.

Understanding Shelley Chu’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.